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Abstract
Background: Inflammation has significant roles in all phases of tumor development, including initiation,
progression and metastasis. Interleukin-10 (IL-10) is a well-known immuno-modulatory cytokine with an anti-
inflammatory activity. Lack of IL-10 allows induction of pro-inflammatory cytokines and hinders anti-tumor
immunity, thereby favoring tumor growth. The IL-10 network is among the most important paths linking cancer
and inflammation. The simple node-and-edge network representation is useful, but limited, hampering the
understanding of the mechanistic details of signaling pathways. Structural networks complete the missing parts,
and provide details. The IL-10 structural network may shed light on the mechanisms through which disease-related
mutations work and the pathogenesis of malignancies.
Results: Using PRISM (a PRotein Interactions by Structural Matching tool), we constructed the structural
network of IL-10, which includes its first and second degree protein neighbor interactions. We predicted the
structures of complexes involved in these interactions, thereby enriching the available structural data. In
order to reveal the significance of the interactions, we exploited mutations identified in cancer patients,
mapping them onto key proteins of this network. We analyzed the effect of these mutations on the
interactions, and demonstrated a relation between these and inflammation and cancer. Our results suggest
that mutations that disrupt the interactions of IL-10 with its receptors (IL-10RA and IL-10RB) and a2-
macroglobulin (A2M) may enhance inflammation and modulate anti-tumor immunity. Likewise, mutations that
weaken the A2M-APP (amyloid precursor protein) association may increase the proliferative effect of APP
through preventing b-amyloid degradation by the A2M receptor, and mutations that abolish the A2M-Kallikrein-
13 (KLK13) interaction may lead to cell proliferation and metastasis through the destructive effect of KLK13 on
the extracellular matrix.
Conclusions: Prediction of protein-protein interactions through structural matching can enrich the available
cellular pathways. In addition, the structural data of protein complexes suggest how oncogenic mutations
influence the interactions and explain their potential impact on IL-10 signaling in cancer and inflammation.
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Background
Inflammation by innate immunity is the first line of
defense against pathogenic infections [1]. It is also
involved in all phases of cancer development, including
tumor initiation, promotion and metastatic dissemina-
tion [2-4]. By triggering immunosuppressive mechan-
isms, inflammation creates a tissue microenvironment
which permits tumor growth and metastasis [2]. Inflam-
matory cells provide growth factors that sustain prolif-
eration, and survival factors that allow escape from
apoptosis; it also contributes to extracellular matrix
(ECM) modifying enzymes, and to pro-angiogenic fac-
tors that facilitate angiogenesis, invasion and ultimately
metastasis [3].
Several lines of evidence link cancer and inflamma-
tion, emphasizing that chronic inflammation contributes
to tumor initiation and progression [5,6]. Chronic
inflammatory bowel disease predisposes individuals to
colon cancer [6] and individuals with chronic hepatitis
are more prone to develop hepatocellular carcinoma [7].
Chronic Helicobacter pylori infection and the resulting
inflammation is associated with gastric cancer [8];
chronic bronchitis with lung cancer; and pancreatitis
with pancreas cancer [9]. Additionally, long term use of
non-steroidal anti-inflammatory drugs (NSAIDs) [10]
which inhibit pro-inflammatory cytokines, like TNF-a
and IL-1b, decrease cancer incidence [11].
Identified in 1989 [12], IL-10 is an anti-inflammatory
cytokine that modulates the immune response: if IL-10 is
not present or functional, inflammation becomes possible.
It restricts the immune response to pathogens and pre-
vents damage to the host. Secreted by immune cells, IL-10
diversely affects cell types in the immune system.
Although it terminates inflammatory responses by
suppressing monocyte/macrophage function, it also acts as
an immunostimulator to promote Th2 response. IL-10
regulates growth and/or differentiation of B cells, NK cells,
cytotoxic and helper T cells, mast cells, granulocytes,
dendritic cells, keratinocytes, and endothelial cells.
Additionally, it stimulates immunoglobulin secretion, and
promotes antibody class switching [13]. Therefore, IL-10
has both immune suppressive (anti-inflammatory) and
immune stimulatory roles (B and T-cell development).
IL-10 deficiency increases the production of IL-1 (a
pro-inflammatory cytokine) and in the absence of IL-10,
IL-1 promotes tumor growth in mice [14]. IL-10 also
prevents development of regulatory T cells (Tregs) and
Myeloid-derived suppressor cells (MDSCs) [14-17]. IL-
10 deficiency leads to an increase in the number of
Tregs and MDSCs in tumor tissue. Tregs and MDSCs
have suppressive roles against tumor-specific immunity
that favor tumor growth [4,14,15]. Apart from its anti-
inflammatory roles, it is associated with activation of
anti-tumor immunity [18]. The presence of IL-10 leads
to tumor regression and increase in tumor-specific
immunogenicity [19]. In contrast, some studies proposed
that blockage of IL-10 signaling promote anti-tumor
immunity [20]. These controversial findings stem from
the pleiotropic effects of IL-10 and different experimen-
tal models (human or animal, in vitro or in vivo, solid
or hematological tumors, presence of exogenous
or endogenous IL-10 or IL-10 inhibitors, etc.) and the
varying site of IL-10 production [19].
IL-10 is a dimeric cytokine [21] that signals through a
tetrameric transmembrane receptor complex, consisting of
two IL-10RA (also known as IL-10R1) and two IL-10RB
(also known as IL-10R2) proteins [22,23]. Both receptors
belong to the class II receptor family, and consist of three
domains: an intracellular domain, a transmembrane
domain, and an extracellular domain [13]. The receptor
complex assembles sequentially: IL-10RA, with higher affi-
nity, binds to IL-10 first and then IL-10RB [21]. IL-10
binding to the extracellular domain of IL-10RA leads to
phosphorylation of JAK1 (Janus Kinase-1) and TYK2
(Tyrosine Kinase-2), that interacts with IL-10RA and
IL-10RB [24], respectively. Specific tyrosine residues on
the intracellular domain of the IL-10RA are then
phosphorylated by these kinases. The STAT3 (Signal
Transducer and Activator of Transcription-3) transcrip-
tion factor binds to those tyrosine residues and gets
phosphorylated. Activated STAT3 then translocates to the
nucleus as a homodimer, and activates transcription of
anti-apoptotic and cell-cycle-progression genes [25,26].
IL-10 has many functional partners, one of which is
the a2-macroglobulin (A2M). IL-10 forms a stable com-
plex with activated A2M [27]. A2M is a large homote-
trameric glycoprotein [28] in the plasma, and in the
extracellular space. It is a proteinase inhibitor, and has a
peptide stretch, called the ‘bait region’. Cleavage of the
bait region by a proteinase leads to a conformational
change in the protein that causes proteinase trapping,
and receptor-mediated endocytosis of the A2M-protei-
nase complex [29]. A2M is also a cytokine transporter.
Many cytokines, including IL-10, and growth factors
bind to A2M non-covalently in vivo [30]. When A2M
forms complexes with IL-10, TGF-b (anti-inflammatory
cytokines) and IFN-g, it accelerates the appearance of
these cytokines in the blood [31,32]. A2M in its native
form increases the half-life of bound cytokines in the
plasma by protecting them from proteolysis [30]. Thus,
at sites of inflammation, A2M concentration rises as a
response to an increase in proteinase level. [27]. A2M
also contributes to the anti-inflammatory response of
IL-10 by preventing its destruction.
IL-10 and IL-10Rs are able to interact with many partner
molecules in the signaling network; however, their detailed
protein structural interactions, as well the corresponding
mutational mechanisms have not been well illustrated.
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In this study, we constructed the structural pathway based
on protein-protein interactions (PPIs). The commonly
used node-and-edge description of pathways, where nodes
represent proteins and edges the interactions between
them, are useful, but do not provide structural interaction
detail [33,34]. Further, in many cases, such as IL-10 and
the receptors in this study, the available structural interac-
tion data of the proteins are incomplete. However, recently
developed computational structural approaches, such as
PRISM (PRotein Interactions by Structural Matching
tool), are capable of predicting PPI and can help filling in
the gaps. PRISM [35,36] is a motif-based protein-protein
interaction prediction tool which uses a knowledge-based
strategy to construct and analyze structural PPI networks.
PRISM is based on the notion that evolution has exploited
favorable structural motifs adapting them to different
functions, in protein folds and at protein-protein-inter-
faces [37-39], lending robustness to its predictions. PRISM
has predicted protein interactions successfully [40,41] for
different pathways, like apoptosis [42], ubiquitination [43],
MAPK [41,44], the Toll-like receptor pathways, [1] and for
identifying drug off-targets [45]. The success of PRISM is
very close to %100 (87 out of 88 cases) in rigid-body
prediction [40]. Recently we have further enhanced it by
introducing ensemble docking, by exploiting different
conformations, and PRISM could predict two thirds of the
‘difficult’ cases of a docking benchmark dataset [41]. Here,
we applied this enhanced PRISM protocol to construct the
structural protein-protein interaction (PPI) network of
IL-10 centered signaling. Importantly, the analysis was
able to identify mutations falling in the interfaces and to
predict their effects on interactions such as of IL-10 with
its receptors, IL-10 with A2M, and A2M with APP and
KLK13. This allowed us to enrich the structural interac-
tion data of IL-10 with its partners, and to analyze the
mechanisms of mutations that lead to inflammation, and
cancer through their impact on predicted interactions.
Methods
Reconstruction of the structural PPI network of IL-10
centered signaling
We used the String server [46] for selecting the first and
second-degree neighbors of IL-10. Only interactions
with experimental evidence and confidence score larger
than 0.4 (the default confidence value) were considered.
There were 4 first-degree and 45 second-degree neigh-
bor proteins of IL-10 (Additional file 1). Overall, there
were 50 proteins comprising the IL-10 centered protein-
protein interaction network.
We used PRISM [35,36] for modeling protein-protein
interactions in the IL-10 centered network. PRISM
searches for the motifs on the target protein surfaces
similar to known interactions considering both geome-
trical complementarities and evolutionary conservation
of hot spots. It treats proteins with at least 15 residues.
To model an interface, PRISM requires the 3D struc-
tures of the proteins of interest (for further details of
the PRISM protocol, see [36]). 39 of these 50 proteins
have structural data in the PDB (corresponding to 958
PDB chains) and we could build homology models for
the remaining 10. IGHV3-6’s sequence information
could not be found, so this protein is not included in
our analysis (Additional file 1 Table S1). The I-TASSER
server [47] was used for homology modeling and the
top 5 models generated by the server were included in
the predictions.
We reduced the redundancy of similar interface archi-
tectures for each protein, using TM (template modeling)-
align [48]. PDB structures having TM-scores larger than
0.5 and RMSD under 2.5Å were classified. Then, a repre-
sentative PDB structure was assigned for each similar
structure group and we ended up with 127 representative
structures for 39 target proteins. The final IL-10 centered
network is composed of 49 proteins and 70 interactions
(Additional file 1 and 2).
Mapping oncogenic mutations onto the interfaces of
predicted protein-protein complexes and in silico
mutagenesis
The reconstructed structural PPI network of IL-10 cen-
tered signaling not only reveals many important details
about the mechanism of protein-protein interactions but
also offers the possibility of observing the effects of
oncogenic mutations. In the case studies presented
below, mutational data related to the proteins in the
network were taken from the COSMIC (Catalogue of
Somatic Mutations in Cancer) database [49,50] and
cBioPortal for Cancer Genomics (The Cancer Genome
Atlas, TCGA) [51]. To map oncogenic mutations, we
identified the interfaces of the modeled protein-protein
complexes using the HotPoint web server, which uses
conservation, solvent accessibility and pairwise residue
potential data to determine computational hot spots
[52]. After the mutational mapping, we performed in
silico mutagenesis to observe the effects of the muta-
tions on the interactions (Figure 1). We computationally
mutated those key residues using the FoldX plugin [53]
for the YASARA molecular viewer [54]. We minimized
the energies of the proteins both before and after the
mutation and then used the mutant structures to re-run
PRISM [35,36] and model the new interaction between
the mutant target and its partner (Figure 1).
Results and discussion
We constructed the IL-10 centered human structural
protein-protein interaction network with first and sec-
ond-degree protein neighbors. This network is com-
posed of 49 proteins and 70 interactions between them
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(Figure 2). Among these 70 interactions, the structure of
only two (IL-10 - IL-10RA and APOE - LRP1) are
deposited in the PDB in a complex form. By using
PRISM, we predicted the structures of the PPI interfaces
and 40 additional interactions were structurally modeled
(Figure 2). As a result, the available structural data
increased from 2 to 42.
In mutation databases, like COSMIC [50,55], there are
thousands of experimentally verified cancer mutations but
the precise mechanisms of mutations, how they change
protein functions and contribute to cancer pathogenesis is
unknown [56]. Proteins function through interactions and
mutations that disrupt interactions also change protein
functions. Some mutations abolish protein interactions,
Figure 1 Mapping oncogenic mutations onto the interfaces of predicted protein-protein complexes and in silico mutagenesis.
Mutational data related to the proteins in the network were taken from the COSMIC database [49,50] and The Cancer Genome Atlas, TCGA [51].
To map oncogenic mutations, we identified the interfaces of the modeled protein-protein complexes using the HotPoint web server [52]. After
the mutational mapping, we performed in silico mutagenesis to observe the effects of mutations - that are on the interface - on the interactions.
We computationally mutated those key residues using the FoldX plugin [53] for the YASARA molecular viewer [54]. We minimized the energies
of the proteins both before and after the mutation and then used the mutant structures to re-run PRISM [35,36] and model the new interaction
between the mutant target and its partner.
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whereas others make the interactions stronger or change
protein folding, favoring aggregation of proteins, as in the
case of formation of amyloids in Alzheimer’s disease [57].
4% of all mutations in the databases were computationally
predicted to be related with protein interactions [56].
Structural knowledge of protein-protein interfaces is
important, allowing mapping mutations and SNPs onto
the structures of the complexes, identifying those falling
on the interfaces, and predicting their effects on protein
interactions [33,58-60]. PRISM is a tool that provides the
opportunity to observe the effects of these mutations on
the interactions. Overall, 879 “missense” and “coding
Figure 2 The protein-protein interaction network of Interleukin-10. There are 49 proteins and 70 interactions in this network and only 2 of
the interactions have structural data in a complex form in the PDB (edges highlighted in yellow). We modeled the interfaces for 40 additional
interactions. Thus there are 42 interactions with interface models (edges highlighted in pink). The remaining 28 edges (out of 70) could not be
modeled and are shown in cyan.
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silent” mutations from COSMIC database [49,50] are
mapped onto 29 target proteins (40 target PDB structures)
in the IL-10 centered network (Table 1 and Additional file
3). Each of the interactions of these 29 target proteins can
be studied for observing the effects of mutations that are
on the interfaces of the predicted models. Below, we pre-
sent four examples of interactions in the reconstructed
structural IL-10 centered network and these interactions
are related to oncogenesis (Figure 3). In these case studies,
we computationally mutated the wild type residues to
their corresponding oncogenic mutation variants and ana-
lyzed the effects on the original interaction.
Case studies
The relation between the interaction of IL-10 with its
receptors and the implications in inflammation & cancer
The structure of the IL-10 and IL-10RA complex is avail-
able in the PDB [21], whereas the IL-10 and IL-10RB
complex structure has not been solved yet. We were able
to model the interaction of IL-10 (PDB code: 2ilkA) with
IL-10RB (3lqmA) using PRISM (Figure 4). The template
interface used in the prediction of this interaction is
2a6aAB (a glycoprotein endopeptidase homodimer) and
the interaction energy score is -15.98 energy units. In
order to confirm our model experimentally, we compared
the interface of the predicted structure with the critical
residues in the binding of IL-10 - IL-10R2 (IL-10RB)
[61], which were determined by surface plasmon reso-
nance and cell-based assays. There is a good agreement
between the predicted interface residues and experimen-
tally determined critical residues in binding assays. Five
out of six residues, Asn21, Arg24, Arg32, His90 and
Ser93, which are determined to be critical in binding, are
also predicted to be in the interface. In order to execute
its function, IL-10 needs to interact with both receptors
IL-10RA and IL-10RB at the same time, as the receptor
complex is a ternary structure [61]. In the PRISM-pre-
dicted model, the receptors can bind to IL-10 without
clashing and can therefore form a ternary complex in
agreement with functional data (Figure 4). PRISM also
predicts the interaction of IL-10 with IL-10RA with
-25.54 energy units, utilizing its own complex structure
as the template interface (1j7vLR). IL-10RA has higher
affinity for IL-10 (-25.54 energy units) compared to the
affinity of IL-10RB for IL-10 (-15.98 energy units). This is
also in line with the sequential mechanism of the ternary
complex formation with IL-10 binding first to IL-10RA,
and then IL-10RB is recruited [61].
Structural details in interactions of IL-10 with its recep-
tors may shed light on the mechanisms of mutations. The
Table 1 The distribution of COSMIC “missense” and “coding silent” mutations mapped onto the target structures in
IL-10 centered network.
Protein PDB Mutation Number Protein PDB Mutation Number
A2M 2p9rA 16 IL10 2ilkA 12
A2M 1bv8A 7 IL10RA 1lqsR 25
A2M 4acqC 139 IL10RB 3lqmA 24
ADAMTS1 2jihB 34 IL1B 3ltqA 16
AMBP 4es7A 12 IL28B 3hhcB 21
ANXA6 1m9iA 35 IL4 1bbnA 9
APOE 2kc3A 5 KLK3 2zchP 29
APOE 2l7bA 8 LEP 1ax8A 11
APP 1tknA 13 LRP1 2knyA 7
APP 3ktmE 9 LYZ 1lz6A 6
APP 2llmA 5 MMP2 3ayuA 20
APP 3nylA 21 NGF 1wwwW 10
APP 1owtA 6 PDGFA 3mjkA 6
APP 3umkA 20 SHBG 1kdkA 6
B2M 1ypzB 22 SIRPG 2jjwA 12
B2M 3ov6A 29 TGFBI 1x3bA 15
BTRC 1p22A 30 TP63 2y9tA 8
CPB2 3d68A 33 TP63 2rmnA 29
CTSB 3pbhA 22 TP63 4a9zC 5
ERBB4 2ahxB 121 UBC 3b0aD 21
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role of IL-10 in cancer was shown by Tanikawa et al. that
IL-10 deficiency causes a rise in the production of IL-1, a
pro-inflammatory cytokine, which in turn leads to
increased tumor growth in mice [14]. Mutations in IL-10
or its receptors may disrupt their interactions, thereby pre-
venting IL-10 signaling. For instance, E41* nonsense muta-
tion in IL-10RB, abolishes the interaction of IL-10 with IL-
10RB, blocking IL-10 signaling. This mutation causes loss
of most of the IL-10RB, including a large portion of the
interface between IL-10 and IL-10RB (Figure 5, the part
drawn in yellow, Table 2). According to the TCGA data,
this mutation is observed in lung adenocarcinoma with 2%
frequency [51]. Furthermore, the R198W substitution
mutation in IL-10RB (from the COSMIC database
Figure 3 The case study interactions highlighted on IL-10 centered network. The thick orange lines indicate four case studies explaining the
relation between mutations on the interfaces of protein-protein complex models and cancer (IL10-IL10RB, IL10-A2M, A2M-KLK13 and A2M-APP).
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[49,50]), also destroys the interaction between IL-10 and
IL-10RB (Table 2), and this mutation is observed in endo-
metrioid carcinoma. Importantly, Figure 6 shows that the
R198W mutation in IL-10RB falls right next to the inter-
face. Blockage of IL-10 signaling may lead to enhanced
inflammation and increased number of Tregs and MDSCs,
which inhibit tumor immunity, allowing tumors to
grow [15].
The association of IL-10 with A2M and its implications for
inflammation and cancer
Here we concentrate on the interaction of IL-10 with a2-
macroglobulin (A2M). A2M mediates the inflammatory
response through acting as a cytokine transporter. A2M
binding to IL-10 facilitates the recruitment of this cyto-
kine to the site of inflammation and triggers an anti-
inflammatory response [31,32]. A2M also protects IL-10
Figure 4 The predicted complex structure of IL-10 with its receptors, IL-10RA and IL-10RB. The complex between IL-10 and IL-10RA is
available in PDB (PDB ID: 1j7v, L and R chains, respectively) and the interaction of IL-10 (PDB ID: 2ilkA) with IL-10RB (PDB ID: 3lqmA) is modeled
by PRISM. Receptors bind to different surfaces of IL-10 that are close to each other.
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from proteolysis [30]. Thus, if the interaction between
these two is disrupted, inflammation will occur [31,32],
which may favor cancer development. Normally, IL-10 is
predicted to bind to A2M with a binding energy score of
-39.2 (Figure 7). We mutated IL-10 computationally
based on the oncogenic mutation to see whether the
interaction is affected. Q56* nonsense mutation in IL-10,
that has been seen in lung adenocarcinoma [50,51], is
observed to abolish the association of IL-10 with A2M.
As can be seen from Figure 7, this nonsense mutation
causes the complete loss of the interface between IL-10
and A2M (the yellow labeled part).
The interaction between A2M with APP and its
implications in cancer
Here, we focus on the interaction between A2M, one of
the interaction partners of IL-10, and b-amyloid precursor
protein (APP). Extracellular cleavage of APP produces
Figure 5 E41* nonsense mutation on IL-10RB protein. IL-10 (2ilkA) is shown in green, blue protein is IL-10RB (3lqmA) and the yellow
segment is the deleted part in E41* nonsense mutant of IL-10RB. This mutation causes the loss of a large part of the protein, including most of
the interface between IL-10 and IL-10RB, so that it blocks the interaction of IL-10RB with IL-10. If IL-10 cannot interact with its receptors,
downstream signaling does not take place and anti-inflammatory outcomes of IL-10 pathway will be lost, allowing inflammation to develop.
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C99, a cell membrane-bound fragment, which is further
cleaved by g-secretase, and releases the intracellular
domain of APP to produce amyloid-b (Ab) [62]. Ab forms
a complex with native A2M and the complex is interna-
lized by the A2M receptor, a low density lipoprotein
receptor-related protein (LRP), and degraded [63].
According to the PRISM results, A2M (PDB ID: 4acqC,
residues 24-1474) forms a stable complex with APP (PDB
ID: 2llmA, residues 686-726) with a binding energy score
of -39.12. The template interface used in the prediction is
1fftAC (ubiquinol oxidase from Escherichia coli). APP is
an integral type I transmembrane protein with a single
transmembrane domain (residues 700-723), a large
extracellular ectodomain (residues 18-699), and a short
cytoplasmic tail (residues 724-770) [62].
APP has been found to be up-regulated in many cancers,
including pancreatic [65], colon [66], and prostate cancer
[67] and squamous cell carcinoma [65]. Gain-of-function
studies indicated that overexpression of APP causes
increased cell proliferation [67,68]. We performed in silico
mutational analysis in order to observe the effect of the
mutations on the A2M - APP interaction, and found a
possible association between abrogation of this interaction
and cancer. Mutations mapping to the interface of the pre-
dicted complex were identified, and a missense mutation,
R945Q, which is observed in colorectal cancer was
selected for further analysis [50,51]. R945 in human A2M
is a hot spot interface residue (Figure 8) and mutating this
residue to glutamine resulted in a noticeable change in the
binding energy score (Table 2). The score for the mutated
structure decreased to -9.12 indicating that substituting
arginine with glutamine greatly weakens the interaction.
This observation suggests that the weakened A2M - APP
interaction could relate to oncogenesis. This idea is sup-
ported by recent studies reporting up-regulation of APP in
several cancers due to its growth-promoting function
[65-68]. Mutations that destabilize this interaction may
prevent or reduce the degradation of Ab by LRP and cause
a rise in APP level [63], which may eventually lead to
increased cancer cellular proliferation.
The structural interaction of A2M with KLK13, and its
implication in cancer
Kallikrein-13 (KLK13, hK13) is a member of the kallik-
rein family and encodes a secreted trypsin-like serine
protease, which is regulated by steroid hormones [69,70].
Experiments show its ability to cleave the major compo-
nents of the extracellular matrix [71]. It is known that
KLK13 can form a complex with the serine protease
inhibitors, including A2M [72]. PRISM was able to pre-
dict an interaction between KLK13 and A2M with an
energy score of -65.22 (Figure 9 and Table 2). The pre-
diction is between the PDB structure 1bv8A (A2M) and a
homology model of KLK13 obtained by the I-TASSER
server [47]. The template interface used in the prediction
is 1g8tAB, a homodimer interface of nuclease.
Although its function is still unclear, KLK13 is used as
a new cancer biomarker in various cancers, including
prostate [73], breast [74], ovarian [75], salivary gland
[71], testicular [76], and non-small cell lung [77] can-
cers. This protein may be involved in the promotion of
cancer cell growth, angiogenesis, metastasis and inva-
sion. The ramification of the R263L mutation on KLK13
is observed in carcinoma from the COSMIC database
[49,50]. We investigated whether this mutation disrupts
the interaction of KLK13 - A2M, created a structurally
predicted mutant KLK13 protein and minimized its
energy. An interaction between the minimized form of
wild type KLK13 and A2M is predicted with an energy
score of -87.73 (implying that the effect of minimization
is insignificant). However, PRISM could not find a
favorable interaction between mutant KLK13 and A2M
(the best prediction has an energy score of +19.48,
Table 2), suggesting disruption of the interaction. Our
data is consistent with the prediction from the HotPoint
server. Disruption of this interaction can allow KLK13
to react with other proteins, which may lead to cleavage
in the major components of the extracellular matrix
[71] and help in the promotion of cancer cell growth,
metastasis and invasion.
Conclusions
Structural PPI networks indicate not only which pro-
teins interact, but also how they interact and the loca-
tion of the interaction sites. Computational techniques
allow us to predict PPIs, mutate proteins and investigate
the effect of those mutations on the PPIs. Here we con-
structed the structural PPI network to explore muta-
tional and pathogenesis mechanisms in inflammatory
diseases and cancer. We focused on the IL-10 centered
Table 2 Comparison of the binding energy scores for
wild type and mutant structures
Target Structures Binding Energy
Score
IL-10 (1j7vL) (wt) IL-10RA (1j7vR) (wt) -25.54
IL-10 (2ilkA) (wt) IL-10RB (3lqmA) (wt) -15.98
IL-10 (2ilkA) (wt) IL-10RB (3lqmA)
(R198W)
-6.09
IL-10 (2ilkA) (wt) IL-10RB (3lqmA) (E41*) N/A
IL-10 (2ilkA) (wt) A2M (1bv8) (wt) -39.2
IL-10 (2ilkA) (Q56*) A2M (1bv8) (wt) N/A
A2M (4acqC) (wt) APP (2llmA) (wt) -39.12
A2M (4acqC) (R945Q) APP (2llmA) (wt) -9.12
hK13 (model) (wt) A2M ( 1bv8A) (wt) -65.22
hK13 (model)
(R236L)
A2M ( 1bv8A) (wt) +19.48
Acuner-Ozbabacan et al. BMC Genomics 2014, 15(Suppl 4):S2
http://www.biomedcentral.com/1471-2164/15/S4/S2
Page 10 of 17
network, as IL-10 is a well-known cytokine with an anti-
inflammatory activity and relation to cancer. Currently
available structural data of the IL-10 pathway are
incomplete, with only 2 interactions available in the
PDB. We utilized homology modeling to obtain the
missing protein structures and a motif-based PPI predic-
tion tool to complete the missing network parts. First
we modeled the structures of 10 proteins and then pro-
vided models for 40 additional interactions. Although
PRISM has a high prediction accuracy, its success to
predict interactions is dependent on the conformation
of the proteins given. We exploited the structures in the
PDB. If the PDB does not include a conformation close
to the bound form of the protein, PRISM cannot predict
the interaction. That is why we missed some interac-
tions on the network. As the PDB gets richer of struc-
tures and different conformations, the success of PRISM
to predict interactions will increase. However, the
Figure 6 R198W substitution mutation on IL-10RB protein. IL-10 (2ilkA) is shown in green, blue protein is IL-10RB (3lqmA). R198, highlighted
in yellow, is the substituted residue on the mutant IL-10RB. This mutation is very close to the interface between IL-10 and IL-10RB and it
abolishes the interaction of IL-10RB with IL-10.
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structural PPI network was extended form 2 interactions
to 42 interactions via predictions. This allowed us to
investigate the effect of clinically observed cancer muta-
tions on our IL-10 centered network. Comparing the
interaction models of the wild type and mutant proteins,
we observed that specific mutations disrupt the interac-
tions, such as between IL-10 and its receptor, IL-10 and
A2M, and A2M and its partners, which may disrupt
immune regulation in cancer. We discovered that muta-
tions of the residues, which were clinically observed in
Figure 7 IL-10 (2ilk, green) is predicted to bind to A2M (1bv8, purple) with a binding energy score of -39.2. The template interface is
1mwqAB, a hypothetical protein from H. influenzae with a putative active-site phosphohistidine. The yellow segment is the deleted part of IL-10
due to Q56* nonsense mutation. The deleted part includes the interface region, so the interaction between IL-10 and A2M is disrupted.
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cancers as hot spots, change the binding energy and abol-
ished or weakened the interactions. Disruption of the
interactions of IL-10 with its receptors (IL-10RA and
IL-10RB) and a-2-macroglobulin (A2M) may lead to
enhanced inflammation, which could promote tumor
growth; blockage of the A2M-APP interaction may lead to
cancerous cellular proliferation through free APP;
blockage of A2M-KLK13 (hK13) interaction can increase
free hK13, which can promote cancer cell growth, metas-
tasis and invasion through damage in the extracellular
matrix. Collectively, by merging mutational and structural
data - available and predicted using our powerful PRISM
tool - and combining it with functional data, we are able
to reveal the consequences of weakening or abolishing
Figure 8 The predicted complex structure of A2M (4acqC, purple) and APP (2llmA, blue) with an energy score of -39.12. Template
interface: 1fftAC (an ubiquinol oxidase). R945, highlighted in yellow, is the mutated residue. The predicted complex structure of mutated A2M
(4acqC, purple) and wt APP (2llmA, blue) has an energy score of -9.12.
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key interactions, and obtain experimentally-testable
mechanisms of oncogenic mutations in the IL-10 network.
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